市場調查報告書
商品編碼
1197291
吸入一氧化氮市場 - 增長、趨勢、COVID-19 影響和預測 (2023-2028)Inhaled Nitric Oxide Market - Growth, Trends, and Forecasts (2023 - 2028) |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
在預測期內,可吸入一氧化氮市場預計將以 4.6% 左右的複合年增長率增長。
美國過敏、哮喘和免疫學協會 (AAAI) 表示,2016 年,美國約有 8.3% 的兒童被發現患有哮喘。 發現 9.2% 的男孩和 7.4% 的女孩患哮喘病的可能性略高於女孩。
兒童哮喘患病率從 2001 年的 8.7% 上升到 2010 年的 9.4%,然後下降到 2016 年的 8.3%。 儘管並非所有變化都具有統計學意義,但亞人口統計研究表明,墨西哥/墨西哥裔美國兒童除外,他們的哮喘患病率從 2001 年的 5.1% 增加到 2016 年的 6.5% 在該群體中觀察到類似的概況。
根據疾病預防控制中心的數據,從 2013 年到 2017 年,美國 18 歲及以上從不吸煙的工作成年人中估計有 240 萬 (2.2%) 患有慢性阻塞性肺病。 在從不吸煙者中,COPD 患病率最高的是信息行業 (3.3%)、採礦業 (3.1%) 以及辦公室和行政支持人員 (3.3%)。 女性的 COPD 患病率高於男性。
此外,根據慢性阻塞性肺疾病全球倡議(GOLD)發布的2019年報告,全球有6500萬人患有慢性阻塞性肺疾病(COPD),每年有300萬人死亡,位居第三。死亡原因。
根據 Matthew Diamond 於 2020 年發表的一篇文章,美國 ARDS 的估計發病率為 64.2-78.9 例/100,000 人年。 25% 的 ARDS 病例最初被歸類為輕度,75% 的病例被歸類為中度或重度。 然而,三分之一的輕度疾病患者會發展為中度或重度疾病。
哮喘的患病率在醫療保健和社會援助行業的工人中也最高,8.8% 的工人在調查時報告患有哮喘。
此外,教育服務業以8.2%的比例位居第二。 因此,預計在預測期內,呼吸系統疾病患病率的增加將有助於北美佔據較大的市場份額。
市場競爭激烈,參與者眾多。 2020 年 2 月,Bellerophon Therapeutics 公佈了其用於治療肺纖維化相關肺動脈高壓(PH-PF)的 INOpulse(脈衝吸入一氧化氮)遞送系統的 2b 期研究的陽性頂線數據。宣布。 Air Liquide Healthcare、Mallinckrodt、Matheson Tri-Gas、Merck KGaA、Novotelis、NuMed Plus、Perma Pure LLC 和 Praxair Technology 等公司佔據了很大的市場份額。
The inhaled nitric oxide market is anticipated to register a CAGR of nearly 4.6%, during the forecast period.
* The American Academy of Allergy Asthma and Immunology (AAAI) states that, in 2016, approximately 8.3% of children in the United States was found to have asthma. Boys were to some extent more likely to have asthma than girls at a rate of 9.2% and 7.4%, respectively.
* Asthma incidence among children increased from 8.7% in 2001 to 9.4% in 2010, and then declined to 8.3% in 2016. Although not all changes were statistically noteworthy, a similar outline was observed among subdemographic groups studied, except the Mexican/Mexican-American children, among whom asthma prevalence increased from 5.1% in 2001 to 6.5% in 2016.
* According to the CDC, during 2013-2017, an estimated 2.4 million (2.2%) US working adults aged more than 18 years who never smoked had COPD. The highest COPD prevalences among persons who never smoked were in the information (3.3%) and mining (3.1%) industries and office and administrative support occupation workers (3.3%). Women had higher COPD prevalences than did men.
* Moreover, as per the 2019 report published by the Global Initiative for Chronic Obstructive Lung Disease (GOLD), 65 million people suffer from chronic obstructive pulmonary disease (COPD) and 3 million die from it each year, making it the third leading cause of death worldwide.
* According to a 2020 article by Matthew Diamond, estimates of the incidence of ARDS in the United States range from 64.2 to 78.9 cases/100,000 person-years. 25% of ARDS cases are initially classified as mild and 75% as moderate or severe. However, a third of the mild cases go on to progress to moderate or severe disease.
* In addition, asthma prevalence was highest among workers in the healthcare and social assistance industry, with 8.8% of workers stating that they had asthma at the time of the survey.
* The source also states that participants in the educational services industry reported the second-highest rate of asthma at 8.2%. Hence, the growing prevalence of respiratory diseases is expected to contribute to the significant market share of North America over the forecast period.
The market is competitive and consists of a number of players. In February 2020, Bellerophon Therapeutics announced positive topline data from the phase 2b study of INOpulse (pulsed, inhaled nitric oxide) delivery system for the treatment of pulmonary hypertension associated with pulmonary fibrosis (PH-PF). Companies like Air Liquide Healthcare, Mallinckrodt, Matheson Tri-Gas Inc., Merck KGaA, Novoteris, Nu-Med Plus, Perma Pure LLC, Praxair Technology Inc., hold the substantial market share in the market.